New Nirsevimab Antibody Rollout Protects Infants Against RSV and Bronchiolitis

The Dominican Republic’s Ministry of Public Health introduced Nirsevimab, a long-acting monoclonal antibody, to protect infants from Respiratory Syncytial Virus (RSV). According to reports from El Caribe and Radiocanal on June 20, 2026, the treatment is available in vaccination centers, including those in the San Juan province, to prevent severe respiratory complications in newborns.

Health authorities in the San Juan province have implemented a strategy to distribute the antibody across all local vaccination centers, according to Radiocanal. This rollout aims to reduce the number of infants hospitalized with severe respiratory distress during peak virus seasons.

SI San Juan characterized the current distribution effort as an “unprecedented strategy” to prevent severe respiratory conditions in the pediatric population. The initiative focuses on providing immediate protection to infants who are most vulnerable to the virus.

How does Nirsevimab protect infants from RSV?

Nirsevimab provides passive immunity by delivering pre-formed antibodies directly to the infant’s system. Unlike a traditional vaccine that prompts the body to create its own immune response, this monoclonal antibody mimics the naturally occurring antibodies that protect infants during pregnancy.

The treatment targets the fusion protein of the RSV virus, which prevents the virus from entering and infecting cells in the respiratory tract. This mechanism helps prevent the onset of bronchiolitis and pneumonia, according to medical data on the drug’s function.

La Voz del Interior reports that the antibody is specifically applied to prevent complications in newborns, who often lack the immune maturity to fight the virus without assistance.

Where can parents access the RSV antibody in the Dominican Republic?

Access to Nirsevimab has been expanded to public health facilities. Radiocanal reports that the antibody is available in all vaccination centers throughout the San Juan province.

CuyoNoticias reports that the region is further expanding protection for babies identified as “at risk,” ensuring that those with underlying health conditions receive priority access to the treatment.

Why is this treatment different from previous RSV options?

The introduction of Nirsevimab represents a significant change from the previous standard of care, Palivizumab. While Palivizumab required monthly injections throughout the RSV season and was limited to high-risk premature infants, Nirsevimab is administered as a single dose.

This shift allows health providers to protect a much larger population of infants rather than only those meeting strict medical criteria for prematurity. The single-dose nature of the treatment reduces the burden on both the healthcare system and the parents.

What happens if RSV goes untreated in newborns?

RSV is a primary cause of bronchiolitis, an inflammation of the small airways in the lungs. According to reports from La Voz del Interior, this condition can lead to severe complications in newborns, including respiratory failure.

Untreated severe cases often require hospitalization for oxygen therapy or mechanical ventilation. By applying Nirsevimab, health authorities aim to lower the rate of these critical admissions in the San Juan province and beyond.

The Ministry of Public Health continues to monitor the distribution of the antibody as part of its broader effort to reinforce child health and prevent seasonal respiratory surges.